147817-50-3

Siramesine (Lu 28-179, 147817-50-3) is a σ2 selective agonist?(IC50’s: σ1 = 17nM, σ2 = 0.2nM).1?It produced non-sedating potent and long-last anxiolytic effects in rodents.2?Siramesine induced caspase-independent programmed cell death in various cancer cell lines?via?increased levels of ROS and lysosomal leakage.3,4,5?Mitochondrial destabilization via loss of membrane potential and increased ROS has also been offered as a mechanism of action for the triggering of cell death by Siramesine.6

Treatment of prostate cancer.

Provenge (Dendreon).

Sigma 1 Receptor

1) Perregaard?et al.?(1995),?Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles; J. Med. Chem.?38?1998 2) Sanchez?et al.?(1997),?The selective sigma2-ligand Lu 280179 has potent anxiolytic effects in rodents; J. Pharmacol. Exp. Ther.?283?1323 3) Ostenfeld?et al.?(2005),?Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress;?Cancer Res.?65?8975 4) Ostenfeld et al. (2008),?Anti-cancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation; Autophagy?4?487 5) Dielschneider?et al.?(2016),?Lysosomotropic agents selectively target chronic lymphocytic leukemia cells due to altered sphingolipid metabolism; Leukemia?30?1290 6) Cesen?et al.?(2013),?Siramesine triggers cell death through destabilization of mitochondria, but not lysosomes; Cell Death Dis.?4?e818